RxDoctor Payments Data

Diana Sitar, DO

Family Medicine · Fort Myers, FLNPI 1174020085

Payments from drug & device makers

$860in general payments, 2019–2025

Across 30 payments — averaging $28.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$253
  • Eisai Inc.$122
  • Novo Nordisk$106
  • GSK$88
  • AstraZeneca$51
  • Merck$45
  • plus $195 from 8 others

What the payments were for

  • Food & beverage$860100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$860 in reported general payments places this provider in the 60th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$36,438
Medicare patients
75
Services billed
807

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide48$75,337
JardianceEmpagliflozin35$39,282
MounjaroTirzepatide28$32,159
EliquisApixaban21$16,699
TrulicityDulaglutide11$16,266
JanuviaSitagliptin Phosphate14$10,710
DapagliflozinDapagliflozin Propanediol24$10,321
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog18$5,213
Rosuvastatin Calcium166$2,865
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate15$2,486
Atorvastatin Calcium132$2,061
SynthroidLevothyroxine Sodium12$1,586
Omeprazole65$1,472
Duloxetine Hcl34$1,346
Levothyroxine Sodium161$1,279

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$106$75,33748 claims
Lilly USA, LLCMounjaro, Trulicity$28$48,42539 claims
MerckJanuvia$45$10,71014 claims
AbbVieSynthroid$18$1,58612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Fort Myers

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →